Do the metabolic benefits of rosiglitazone vary when given alone or in combination with sulfonylurea compounds in hyperglycemic patients with type 2 diabetes? Abbasi, F., Chu, J., McLaughlin, T., Lamendola, C., Schaaf, P., Reaven, G. AMER DIABETES ASSOC. 2003: A441

View details for Web of Science ID 000183173801894